Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Engene Holdings Inc (ENGN)

Engene Holdings Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 641,512
  • Shares Outstanding, K 43,581
  • Annual Sales, $ 0 K
  • Annual Income, $ 30 K
  • 60-Month Beta -0.49
  • Price/Sales N/A
  • Price/Cash Flow 7,853.43
  • Price/Book N/A
Trade ENGN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.47
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.47
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.49 +8.97%
on 04/18/24
18.16 -19.06%
on 03/27/24
-3.30 (-18.34%)
since 03/26/24
3-Month
7.31 +101.18%
on 02/13/24
18.40 -20.11%
on 03/26/24
+6.99 (+90.65%)
since 01/26/24

Most Recent Stories

More News
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...

ENGN : 14.23 (-3.33%)
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...

ENGN : 14.23 (-3.33%)
/C O R R E C T I O N -- enGene Inc./

In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by...

ENGN : 14.23 (-3.33%)
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...

ENGN : 14.23 (-3.33%)
enGene To Present at the Leerink Partners Global Biopharma Conference

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...

ENGN : 14.23 (-3.33%)
enGene Announces Oversubscribed $200 Million Private Placement Financing

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...

ENGN : 14.23 (-3.33%)
enGene Announces Leadership Succession Plan

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...

ENGN : 14.23 (-3.33%)
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

/CNW/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for...

ENGN : 14.23 (-3.33%)
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with...

ENGN : 14.23 (-3.33%)
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

/CNW/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for...

ENGN : 14.23 (-3.33%)
HTGC : 19.07 (+0.63%)

Business Summary

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

See More

Key Turning Points

3rd Resistance Point 15.73
2nd Resistance Point 15.46
1st Resistance Point 15.09
Last Price 14.23
1st Support Level 14.45
2nd Support Level 14.18
3rd Support Level 13.81

See More

52-Week High 43.00
Fibonacci 61.8% 29.13
Fibonacci 50% 24.84
Fibonacci 38.2% 20.56
Last Price 14.23
52-Week Low 6.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar